Does long-term probucol treatment prevent secondary cardiovascular events in patients with heterozygous familial hypercholesterolemia?
Long-term probucol treatment may be effective for secondary prevention of cardiovascular events in high-risk patients with heterozygous familial hypercholesterolemia.
Long-term probucol treatment may prevent secondary attack in a higher cardiovascular risk population of heterozygous FH.
Yamashita et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: